EUVIMEDEUVIMED entdecken
Crossref

Short‐term administration of oclacitinib with concomitant medications in canine epitheliotropic lymphoma: A retrospective study of eight dogs

Yuta Baba iD, Tomo Asakura, Saki Obayashi, Miyuki Yamada, Motoki Otsuka, Shinya Morikawa, Angeline Teh iD, Ikki Mitsui, Takafumi Osumi

Veterinary Dermatology · 2025-10 · 36 (5) · 660-667

DOI: 10.1111/vde.13366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary Dermatology, online erschienen am 17.06.2025. Verfasst von Yuta Baba und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tokyo Veterinary Dermatology Center, Shibuya, Tokyo, Japan. Hauptthemen laut MEDLINE: Pyrimidines, Dog Diseases, Sulfonamides, Skin Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Canine cutaneous epitheliotropic lymphoma (CEL) is a rare neoplastic disease with poor prognosis. Oclacitinib, a Janus kinase inhibitor primarily used to treat allergic and atopic dermatitis in dogs, may also cause other skin diseases.

Objectives

This study aimed to evaluate the efficacy of oclacitinib in the treatment of canine cutaneous lymphoma. Animals Eight client‐owned dogs with CEL were included in the study. Materials and Methods The dogs were administered oclacitinib. This study examined the immunological characteristics, time to treatment initiation, dosage, cutaneous lesions and pruritus, adverse events, survival time and prior oclacitinib use.

Results

Only one of the eight dogs (12.5%) showed symptomatic improvement after oclacitinib treatment, with no clinical improvement observed in the other cases. Improvement in pruritus was noted in only one dog. Adverse events included mild leucopenia in one dog, which did not significantly affect prognosis. The median survival time after diagnosis was 228.5 days. Conclusions and Clinical Relevance These results suggest that oral oclacitinib has limited efficacy in the treatment of canine CEL. Larger prospective studies are recommended to further investigate the optimal dose, treatment duration and potential combination therapies involving oclacitinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesDog DiseasesSulfonamidesSkin NeoplasmsLymphomaAntineoplastic AgentsAnimalsDogsRetrospective StudiesMaleFemaleTreatment Outcome

Stichwörter der Autor:innen

Janus kinase inhibitorsT‐cellcutaneousdogslymphomaskin neoplasms

Substanzen

PyrimidinesoclacitinibSulfonamidesAntineoplastic Agents

Autor:innen und Institutionen

  • Tokyo Veterinary Dermatology Center, Shibuya, Tokyo, Japan.
  • Animal Medical Center Chiba Seaside, Narashino, Chiba, Japan.
  • Dog and Cat Hospital Itozu, Kokura, Fukuoka, Japan.
  • Kameido Animal General Hospital, Sumida, Tokyo, Japan.
  • Furuya Animal Hospital, Shinagawa, Tokyo, Japan.
  • Morikawa Animal Medical Center, Ota, Tokyo, Japan.

ORCID-Profile: Yuta Baba, Angeline Teh

Zitieren

APA

Baba, Y., Asakura, T., Obayashi, S., Yamada, M., Otsuka, M., Morikawa, S., Teh, A., Mitsui, I., & Osumi, T. (2025). Short‐term administration of oclacitinib with concomitant medications in canine epitheliotropic lymphoma: A retrospective study of eight dogs. Veterinary Dermatology, 36(5), 660-667. https://doi.org/10.1111/vde.13366

Vancouver

Baba Y, Asakura T, Obayashi S, Yamada M, Otsuka M, Morikawa S, et al. Short‐term administration of oclacitinib with concomitant medications in canine epitheliotropic lymphoma: A retrospective study of eight dogs. Veterinary Dermatology. 2025;36(5):660-667. doi:10.1111/vde.13366

BibTeX
@article{Baba2025,
  author = {Baba, Yuta and Asakura, Tomo and Obayashi, Saki and Yamada, Miyuki and Otsuka, Motoki and Morikawa, Shinya and Teh, Angeline and Mitsui, Ikki and Osumi, Takafumi},
  title = {Short‐term administration of oclacitinib with concomitant medications in canine epitheliotropic lymphoma: A retrospective study of eight dogs},
  journal = {Veterinary Dermatology},
  year = {2025},
  volume = {36},
  number = {5},
  pages = {660--667},
  doi = {10.1111/vde.13366}
}
Kostenlos starten →